Intrinsic value of Allied Healthcare Products - AHPI

Previous Close

$2.06

  Intrinsic Value

$1.18

stock screener

  Rating & Target

sell

-43%

  Value-price divergence*

-53%

Previous close

$2.06

 
Intrinsic value

$1.18

 
Up/down potential

-43%

 
Rating

sell

 
Value-price divergence*

-53%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of AHPI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.86
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  36
  37
  38
  39
  40
  41
  42
  44
  45
  47
  49
  51
  53
  55
  57
  60
  62
  65
  68
  71
  74
  78
  81
  85
  89
  93
  98
  102
  107
  113
  118
Variable operating expenses, $m
 
  37
  38
  39
  40
  41
  42
  44
  45
  47
  49
  51
  53
  55
  57
  60
  62
  65
  68
  71
  74
  78
  81
  85
  89
  93
  98
  102
  107
  113
  118
Fixed operating expenses, $m
 
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  4
Total operating expenses, $m
  38
  39
  40
  41
  42
  43
  44
  46
  47
  49
  52
  54
  56
  58
  60
  63
  65
  68
  71
  74
  77
  81
  84
  89
  93
  97
  102
  106
  111
  117
  122
Operating income, $m
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
EBITDA, $m
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
Interest expense (income), $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Earnings before tax, $m
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  2
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  23
  21
  22
  22
  23
  24
  25
  25
  26
  27
  28
  29
  31
  32
  33
  35
  36
  38
  40
  41
  43
  45
  47
  50
  52
  54
  57
  60
  63
  66
  69
Adjusted assets (=assets-cash), $m
  21
  21
  22
  22
  23
  24
  25
  25
  26
  27
  28
  29
  31
  32
  33
  35
  36
  38
  40
  41
  43
  45
  47
  50
  52
  54
  57
  60
  63
  66
  69
Revenue / Adjusted assets
  1.714
  1.762
  1.727
  1.773
  1.739
  1.708
  1.680
  1.760
  1.731
  1.741
  1.750
  1.759
  1.710
  1.719
  1.727
  1.714
  1.722
  1.711
  1.700
  1.732
  1.721
  1.733
  1.723
  1.700
  1.712
  1.722
  1.719
  1.700
  1.698
  1.712
  1.710
Average production assets, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Working capital, $m
  10
  8
  8
  9
  9
  9
  9
  10
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  16
  16
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
Total debt, $m
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  2
  2
  2
  3
  3
  3
  4
  4
  4
  5
  5
  6
  6
  7
  7
  8
  9
  9
  10
  11
  11
Total liabilities, $m
  5
  5
  5
  5
  6
  6
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  9
  10
  10
  11
  11
  12
  12
  13
  14
  14
  15
  16
  16
Total equity, $m
  18
  16
  17
  17
  18
  18
  19
  19
  20
  21
  22
  22
  23
  24
  25
  26
  28
  29
  30
  32
  33
  34
  36
  38
  40
  41
  43
  46
  48
  50
  52
Total liabilities and equity, $m
  23
  21
  22
  22
  24
  24
  25
  25
  26
  27
  29
  29
  30
  32
  33
  34
  37
  38
  39
  42
  43
  45
  47
  50
  52
  54
  57
  60
  63
  66
  68
Debt-to-equity ratio
  0.000
  0.010
  0.010
  0.020
  0.030
  0.040
  0.050
  0.050
  0.060
  0.070
  0.080
  0.090
  0.100
  0.110
  0.120
  0.120
  0.130
  0.140
  0.150
  0.150
  0.160
  0.170
  0.170
  0.180
  0.190
  0.190
  0.200
  0.200
  0.210
  0.210
  0.220
Adjusted equity ratio
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762
  0.762

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
Depreciation, amort., depletion, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Funds from operations, $m
  1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
Change in working capital, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
Cash from operations, $m
  0
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -5
  -6
  -6
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from investing activities, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Free cash flow, $m
  0
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -5
  -6
  -6
Issuance/(repayment) of debt, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
Issuance/(repurchase) of shares, $m
  0
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
Cash from financing (excl. dividends), $m  
  0
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  7
  7
  7
  7
  8
  8
  8
Total cash flow (excl. dividends), $m
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
Retained Cash Flow (-), $m
  3
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
Prev. year cash balance distribution, $m
 
  2
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  0
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  0
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  82.5
  67.8
  55.5
  45.3
  36.9
  30.0
  24.3
  19.7
  16.0
  12.9
  10.5
  8.5
  6.9
  5.6
  4.6
  3.7
  3.0
  2.5
  2.0
  1.6
  1.3
  1.1
  0.9
  0.8
  0.6
  0.5
  0.4
  0.4
  0.3
  0.2

Allied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospital and alternate site settings worldwide. The company’s respiratory care/anesthesia products comprise air compressors, calibration equipment, humidifiers, croup tents, and equipment dryers, as well as respiratory disposable products, such as oxygen tubing, facemasks, cannulas, and ventilator circuits; and home respiratory care products include aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, and portable suction equipment. It also provides medical gas equipment, which comprise construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment, comprising flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure, regulate, monitor, and transfer medical gases from walled piping or equipment to patients; and disposable oxygen cylinders to provide oxygen for short periods. In addition, the company offers medical products that include respiratory/resuscitation products comprising demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products, such as spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. The company serves hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers, and others. Allied Healthcare Products, Inc. was founded in 1979 and is headquartered in St. Louis, Missouri.

FINANCIAL RATIOS  of  Allied Healthcare Products (AHPI)

Valuation Ratios
P/E Ratio -4.1
Price to Sales 0.2
Price to Book 0.5
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate 2.9%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate -100%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -8.3%
Ret/ On Assets - 3 Yr. Avg. -9%
Return On Total Capital -10.3%
Ret/ On T. Cap. - 3 Yr. Avg. -10.6%
Return On Equity -10.3%
Return On Equity - 3 Yr. Avg. -10.6%
Asset Turnover 1.5
Profitability Ratios
Gross Margin 19.4%
Gross Margin - 3 Yr. Avg. 19.6%
EBITDA Margin -2.8%
EBITDA Margin - 3 Yr. Avg. -3.7%
Operating Margin -5.6%
Oper. Margin - 3 Yr. Avg. -6.5%
Pre-Tax Margin -5.6%
Pre-Tax Margin - 3 Yr. Avg. -6.5%
Net Profit Margin -5.6%
Net Profit Margin - 3 Yr. Avg. -6.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

AHPI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AHPI stock intrinsic value calculation we used $36 million for the last fiscal year's total revenue generated by Allied Healthcare Products. The default revenue input number comes from 2016 income statement of Allied Healthcare Products. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AHPI stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for AHPI is calculated based on our internal credit rating of Allied Healthcare Products, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Allied Healthcare Products.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AHPI stock the variable cost ratio is equal to 100%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $2 million in the base year in the intrinsic value calculation for AHPI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Allied Healthcare Products.

Corporate tax rate of 27% is the nominal tax rate for Allied Healthcare Products. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AHPI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AHPI are equal to 0%.

Life of production assets of 10 years is the average useful life of capital assets used in Allied Healthcare Products operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AHPI is equal to 22.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $18 million for Allied Healthcare Products - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 3.809 million for Allied Healthcare Products is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Allied Healthcare Products at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
RMD ResMed 73.07 62.77  hold
INGN Inogen 93.96 39.78  str.sell
TFX Teleflex 210.66 86.78  str.sell
IVC Invacare 13.45 2.90  str.sell
BDX Becton Dickins 197.69 58.16  str.sell
ELMD Electromed 6.20 17.91  str.buy

COMPANY NEWS

▶ Allied Healthcare gets another Nasdaq warning   [Mar-01-16 08:30AM  at bizjournals.com]
▶ OxySure (OXYS) Ramps Up Production as Growth Continues   [Feb-25-16 08:00AM  Accesswire]
▶ Allied Healthcare Products, Inc. Earnings Q1, 2016   [Nov-30  10:11AM  Capital Cube]
▶ Allied Healthcare Products gets Nadaq warning   [Oct-01  07:10AM  at bizjournals.com]
▶ Allied Healthcares loss narrows in fiscal 2015   [Sep-29  05:45PM  at bizjournals.com]
▶ 10-Q for Allied Healthcare Products, Inc.   [May-15  08:09PM  at Company Spotlight]
▶ 10-Q for Allied Healthcare Products, Inc.   [Feb-15  07:07PM  at Company Spotlight]
▶ UAB ranks among nation's top accredited online colleges   [Feb-12  12:50PM  at bizjournals.com]
▶ 10-Q for Allied Healthcare Products, Inc.   [Nov-14  07:09PM  Company Spotlight]
▶ Ebola Stock Short Interest Surprise   [Nov-12  02:10PM  at 24/7 Wall St.]
▶ Ebola Stocks on the Move   [Oct-16  02:05PM  at 24/7 Wall St.]
▶ Ebola Fears Driving Ebola Stock Winners   [Oct-13  10:00AM  24/7 Wall St.]
▶ 10-K for Allied Healthcare Products, Inc.   [Sep-28  08:09PM  Company Spotlight]
▶ 3 Stocks Pushing The Health Services Industry Lower   [Jul-25  04:01PM  at TheStreet]
▶ 3 Stocks Advancing The Health Services Industry   [Jul-18  04:01PM  at TheStreet]
▶ Allied Healthcare Products Reports Second Quarter Loss   [Feb-13  05:44PM  PR Newswire]
▶ Allied Healthcare Products Reports Second Quarter Loss   [Feb-11  03:16PM  PR Newswire]
▶ Allied Healthcare reports Q1 net loss of $411,032   [Nov-07-12 07:14PM  at bizjournals.com]
▶ Allied Healthcare CEO Refslands pay up 6 percent in fiscal 2012   [Oct-09-12 11:50AM  at bizjournals.com]
▶ Allied Healthcare posts Q4 loss as sales fall 12 percent   [Sep-28-12 03:10PM  at bizjournals.com]
▶ Allied Healthcare to pay Armstrong Medical $275,000 in settlement   [Jun-14-12 02:26PM  at bizjournals.com]
▶ Allied Healthcare reports Q3 loss of $145,787 as sales fall   [May-10-12 08:26PM  at bizjournals.com]
▶ Allied Healthcare's Q2 profit drops 81%   [Feb-14-12 08:21AM  at bizjournals.com]
▶ Allied Healthcare Q2 net income falls 81%   [Feb-13-12 07:20PM  at bizjournals.com]
▶ ResMed Inc. Earnings: Keeping the Profitability Streak Alive   [Jan-26-12 05:23PM  Wall St. Cheat Sheet]
▶ ResMed Inc. Second Quarter Earnings Sneak Peek   [Jan-23-12 11:47AM  Wall St. Cheat Sheet]
▶ Stocks rise on Spain debt auction, China growth news   [Jan-17-12 01:09PM  at bizjournals.com]
▶ Market update: Stocks lower on final trading day of the year   [Dec-30-11 12:46PM  at bizjournals.com]
▶ 8 Healthcare Stocks With High P/E Ratios   [Dec-29-11 04:09PM  at Seeking Alpha]
▶ Market update: Stocks flat in morning trading   [Dec-27-11 12:45PM  at bizjournals.com]
▶ Market Wrap: Late slide sends stocks lower   [Dec-13-11 04:30PM  at bizjournals.com]
▶ St. Louis stocks mixed on jobs report   [Dec-02-11 03:31PM  at bizjournals.com]
▶ ALLIED HEALTHCARE PRODUCTS INC Financials   [Nov-15-11 01:04PM  EDGAR Online Financials]
▶ Allied Healthcare posts loss in Q1   [Nov-08-11 07:05PM  at bizjournals.com]
▶ ResMed Inc. Earnings Cheat Sheet: Margins Shrink as Net Income Drops   [Oct-24-11 05:00PM  Wall St. Cheat Sheet]
▶ ResMed, Inc. First Quarter Earnings Sneak Peek   [Oct-19-11 11:43AM  Wall St. Cheat Sheet]
Stock chart of AHPI Financial statements of AHPI
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.